mobocertinib + itraconazole

**Mobocertinib + itraconazole** is a combination of mobocertinib, an oral small molecule tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), and itraconazole, a strong CYP3A inhibitor antifungal. Mobocertinib is primarily used for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Itraconazole is known to significantly increase mobocertinib plasma exposure by inhibiting CYP3A4/5-mediated metabolism, resulting in higher systemic concentrations and extended half-life of mobocertinib and its active metabolites (AP32960 and AP32914). This combination is clinically significant for drug-drug interaction studies and is not recommended for therapeutic coadministration due to the risk of increased mobocertinib toxicity[1][2][4].

Other names

mobocertinibitraconazole